Predictive Oncology

We were fortunate to have had Shannon Perrine from WTAE, Pittsburgh's Action News Four, visit Predictive Oncology to learn more about how we are using Artificial Intelligence to expedite drug discovery in our ongoing fight against cancer. The segment, which will air in May, promises to cast a new light on how a Pittsburgh company is making a meaningful difference in the development of cancer drugs on a global scale.

WTAE-TV Pittsburgh GMA News

At Predictive Oncology, we know there is a cancer patient waiting for therapies to be developed, hoping for a new and effective treatment to get into the hands of the clinician that can help improve their quality of life, extend their life or even cure their cancer. In honor of International Women’s Day, we would like to thank the women at Predictive Oncology who work tirelessly to bring that hope to cancer patients.

More than AI: The proof of concept study we conducted at Predictive Oncology demonstrates our ability to move molecules forward with high-confidence predictions using our proprietary PEDAL platform that goes beyond machine learning and incorporates wet lab experiments from our biobank, with the domain expertise from our scientists and data from our AI.
https://hubs.la/Q01FJ_KS0

More than AI The proof of concept study we conducted at Predictive Oncology demonstrates our ability to move molecules forward with high-confidence predictions using our ...

Proactive Investor’s Natalie Stoberman met with Raymond F. Vennare, CEO of Predictive Oncology, and Javier Torres-Roca, MD, Co-Founder and CEO of Cvergenx, Inc., to discuss their strategic partnership to create the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence.

You can view the interview here and learn more about how this powerful collaboration will leverage Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities with the Cvergenx precision genomics radiation therapy platform.

Predictive Oncology partners with Cvergenx to create new genomics-based A.I. radiation therapy Predictive Oncology CEO Raymond Vennare and Cvergenx CEO Javier Torres-Roca join Natalie Stoberman to share their new partnership to develop the first-ever...

In this "Chalk Talk Jim" podcast with James Jordan, Dr. Pamela Bush, Chief Business Officer at Predictive Oncology, talks about her work connecting science and business to advance the discovery and development of drugs against cancer. She explains how the company’s PEDAL platform can predict response for a specific drug-tumor pairing and shares how her experience prepared her for this new role.

Adapting to the Changing World of Drug Discovery and Development - Outcomes Rocket Pam Bush talks about advancing the development of drugs against cancer assisted by predictive AI, ML technology, and a library of tumor samples.

Predictive Oncology is pleased to announce that we have signed an agreement to form a strategic partnership that has the potential to revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery.

By applying Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities (PEDAL), and the Cvergenx precision genomics radiation therapy platform (pGRTTM), the two companies will pursue ways in which to optimize radiotherapy (RT) to improve patient outcomes in a way that has never been done before.

More than one million patients are treated with radiotherapy every year in the US. If the overall survival of RT-treated patients is improved by 4%, that would translate into 40,000 lives, almost equivalent to eradicating breast cancer. We believe this knowledge can improve the clinical outcome of patients treated with radiotherapy.

The pGRT platform is currently being evaluated in a Phase 2 prospective clinical trial for triple negative breast cancer (NCT05528133) at the Moffitt Cancer Center. Cvergenx is a spin-out of the Moffitt Cancer Center.

Learn more about the news here:
https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-and-cvergenx-announce-partnership-develop-0

Moffitt Cancer Center

Predictive Oncology welcomes FluGen to our growing family of partners. FluGen, Inc. is a clinical-stage vaccine company transforming vaccine efficacy in respiratory diseases. The company’s lead candidate M2SR stimulates mucosal, humoral, and cellular immunity and protection against infection and illness across seven years of virus drift. M2SR induces a durable antibody response and has shown activity as a vaccine vector for other respiratory vaccines and infectious diseases, including a COVID-19/flu combination.

If you work for an academic or research institution and are involved in oncology drug discovery, we invite you to apply to the Predictive Oncology ACE program that we launched today.

Our company created ACE (Accelerating Compound Exploration) to grant early-stage academic drug development groups and technology transfer offices access to our PEDAL platform. PEDAL pairs active machine learning with an extensive biobank of 150K privately held tumor samples and in vitro assay results to help evaluate drug compounds and enable more informed selection of drug-tumor type combinations.

The deadline for the first round of applications is March 31.

ACE intake - Predictive Oncology ACE program Introducing the Predictive Oncology ACE program Welcome to the ACE (Accelerating Compound Exploration) program, an initiative we are launching at Predictive Oncology to help academic and research institutions to advance their drug discovery. Our company created ACE to grant early-stage a...

Proactive Investors sat down to talk with Dr. Pamela Bush about her appointment as Chief Business Officer and the vision she brings to the company in this new role.

Dr. Pamela Bush introduced as new Chief Business Officer for Predictive Oncology Predictive Oncology Chief Business Officer Dr. Pamela Bush joins Natalie Stoberman from the Proactive studio to share her plans for her new role with the...

“The ability to use the PEDAL platform and testing in actual tumor samples to determine the drug response of these tumors is going to be…invaluable to drug discovery teams,” Pamela Bush, Ph.D., MBA, Chief Business Officer, Predictive Oncology.
https://hubs.la/Q01CCXZW0

Determining drug response The ability to use the PEDAL platform and testing in actual tumor samples to determine the drug response of these tumors is going to be invaluable to drug di...

Precision Oncology News highlighted Predictive Oncology’s pursuit of partnerships with biopharma companies to “provide early insights that sponsors can use to prioritize drugs for development and identify biomarker-informed indications.” Read more here:
https://hubs.la/Q01Clc6C0

Predictive Oncology looks to improve precision cancer Rx development with AI-driven platform - Predictive Oncology As appeared in Precision Oncology News. NEW YORK – Predictive Oncology wants to ink more partnerships with biopharmaceutical companies and demonstrate the ability of its commercially available PEDAL platform to provide early insights that sponsors can use to prioritize drugs for development and id...

Today is World Cancer Day.

Someone at this very moment is being told that they have cancer. It will stun them. It will frighten them. It will take their breath away. It is because of them, and for them, that World Cancer Day exists--a day that was created to raise awareness about the prevention, detection and treatment of cancer.

Every single day that we walk through the doors of Predictive Oncology, we are committed to working together to give cancer patients hope. Whether this means helping biopharma companies discover new molecules, find new compounds or enable them to discover more effective ways to repurpose drugs — we exist to make that happen.

At the end of the day, we know very well that there are cancer patients waiting for therapies to be developed. To extend their lives. To improve their lives. Maybe even save their lives. This is our vision. This is our mission. This is the hope that we provide.

World Cancer Day is every day behind the doors of Predictive Oncology.